Skip to main content
. Author manuscript; available in PMC: 2011 Nov 1.
Published in final edited form as: Cancer Res. 2010 Oct 12;70(21):8907–8916. doi: 10.1158/0008-5472.CAN-10-0353

Figure 5. Nedd9 status does not affect response to inhibitors of Aurora-A or EGFR.

Figure 5

A. Experiment as in 4A with the Aurora-A inhibitor C1368, for 2 cell lines of each genotype, and resulting data averaged (IC50 1.11 μM versus 2.21 μM; p value is not significant). Similar results were obtained with a second Aurora-A inhibitor, PHA 680632; results not shown. B. Experiment as in A with the EGFR inhibitor erlotinib (IC50 1.29 μM versus 1.37μM; p value is not significant) indicates no cell genotype-dependent difference in IC50 value. C. Immunoblots of tumor lysates as in 4C. D. Expression and activation (reflected by levels of autophosphorylated forms) of Src and Lyn in MMTV-PyVT;Nedd9−/− versus MMTV-PyVT;Nedd9+/+ cell lines treated for 2 hours with 200 nM dasatinib.